NDC 49502-196

SEMGLEE

Insulin Glargine

SEMGLEE is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Mylan Specialty L.p.. The primary component is Insulin Glargine.

Product ID49502-196_2ed619e6-67e7-402e-a3bc-7cd7b81d59bf
NDC49502-196
Product TypeHuman Prescription Drug
Proprietary NameSEMGLEE
Generic NameInsulin Glargine
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2020-08-31
Marketing End Date2022-11-30
Marketing CategoryBLA / BLA
Application NumberBLA210605
Labeler NameMylan Specialty L.P.
Substance NameINSULIN GLARGINE
Active Ingredient Strength100 [iU]/mL
Pharm ClassesInsulin [CS],Insulin Analog [EPC]
NDC Exclude FlagN

Packaging

NDC 49502-196-75

5 SYRINGE in 1 CARTON (49502-196-75) > 3 mL in 1 SYRINGE (49502-196-35)
Marketing Start Date2020-08-31
Marketing End Date2022-11-30
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "SEMGLEE" or generic name "Insulin Glargine"

NDCBrand NameGeneric Name
49502-195SEMGLEESEMGLEE
49502-196SEMGLEESEMGLEE
0002-7715BASAGLARInsulin glargine
0002-8214BASAGLARInsulin glargine
0088-2220Lantusinsulin glargine
0088-2219Lantus Solostarinsulin glargine
0024-5869TOUJEOinsulin glargine
0024-5871TOUJEO Maxinsulin glargine

Trademark Results [SEMGLEE]

Mark Image

Registration | Serial
Company
Trademark
Application Date
SEMGLEE
SEMGLEE
88613561 not registered Live/Pending
Mylan Pharmaceuticals, Inc.
2019-09-11
SEMGLEE
SEMGLEE
86970764 not registered Dead/Abandoned
Mylan Pharmaceuticals, Inc.
2016-04-11

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.